Department of Radiology, Adiyaman Training & Research Hospital, Turkey.
Department of Chest Diseases, Medicine Faculty of Adiyaman University, Turkey.
Clin Imaging. 2021 Dec;80:1-5. doi: 10.1016/j.clinimag.2021.06.034. Epub 2021 Jun 26.
To measure the degree of fatty liver using non-contrast enhanced chest computed tomography (CT) and investigate its relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19) in adult patients.
This retrospective study included consecutive patients who had been diagnosed with COVID-19 using real-time reverse-transcription polymerase chain reaction (RT-PCR) and subsequently underwent non-contrast enhanced chest CT between October 10 and December 10, 2020. Hepatic attenuation values were measured from Couinaud segments 2, 4, and 8 based on the CT images and the relationships between these values and the Pneumonia Severity Score (PSS), requirement of hospitalization, and the length of hospital and intensive care unit (ICU) stay were analyzed.
The study included 414 patients (182 were female, 43.96%), among whom 106 (25.6%) were diagnosed with hepatosteatosis (HS). In the patients with HS, the PSS scores were higher (10.8 ± 4.96 vs. 8.07 ± 5.12; p < 0.001), and 69 (65%) received inpatient care. Moreover, the number of HS patients who received inpatient care was 1.99 (95% confidence interval (CI) 1.26-3.15, p < 0.003) times higher than that of the non-HS patients. No significant difference was found between the HS and non-HS patients with regard to the length of hospital or ICU stay.
HS can be easily evaluated using non-contrast enhanced chest CT in COVID-19 patients and can be used as a prognostic marker to determine the requirement of hospitalization.
使用非增强胸部计算机断层扫描（CT）测量脂肪肝的程度，并研究其与成人 2019 年冠状病毒病（COVID-19）严重程度和预后的关系。
本回顾性研究纳入了 2020 年 10 月 10 日至 12 月 10 日期间，经实时逆转录聚合酶链反应（RT-PCR）确诊为 COVID-19 且随后接受非增强胸部 CT 检查的连续患者。根据 CT 图像，从 Couinaud 段 2、4 和 8 测量肝衰减值，并分析这些值与肺炎严重程度评分（PSS）、住院需求以及住院和重症监护病房（ICU）住院时间之间的关系。
本研究纳入了 414 例患者（女性 182 例，占 43.96%），其中 106 例（25.6%）诊断为肝脂肪变性（HS）。在 HS 患者中，PSS 评分更高（10.8±4.96 与 8.07±5.12；p<0.001），且 69 例（65%）接受住院治疗。此外，需要住院治疗的 HS 患者人数是非 HS 患者的 1.99 倍（95%置信区间 1.26-3.15，p<0.003）。HS 患者与非 HS 患者的住院或 ICU 住院时间无显著差异。
在 COVID-19 患者中，使用非增强胸部 CT 可以轻松评估 HS，并可作为预测住院需求的预后标志物。
